InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
mick Grandfathered
02/21/17 8:51 AM
profile icon
mick Grandfathered
02/21/17 8:50 AM
profile icon
Phoenix300 Free
02/07/17 8:56 AM
profile icon
stocktrademan Free
09/03/16 4:39 PM
profile icon
stocktrademan Free
08/12/16 12:28 PM
profile icon
venturecapp Free
06/01/16 11:21 AM
profile icon
venturecapp Free
05/31/16 1:00 PM
profile icon
Book Em Dan O Free
05/26/16 4:12 PM
profile icon
bigstocksnbonds Free
02/12/16 8:26 PM
profile icon
Canoepaddler Free
02/12/16 8:13 PM
profile icon
bigstocksnbonds Free
02/12/16 8:09 PM
profile icon
Canoepaddler Free
02/12/16 7:47 PM
profile icon
bigstocksnbonds Free
02/04/16 9:28 PM
profile icon
stocktrademan Free
12/12/15 3:51 PM
profile icon
basssque Free
10/23/15 4:07 PM
profile icon
TheFinalCD PremiumMember
09/09/15 9:21 AM
profile icon
stocktrademan Free
09/04/15 4:13 PM
profile icon
stocktrademan Free
10/02/14 11:16 AM

Flexion Therapeutics, Inc. (FLXN) RSS Feed

Followers
5
Posters
22
Posts (Today)
0
Posts (Total)
70
Created
10/02/14
Type
Free
Moderators
Flexion Therapeutics, Inc. 10 Mall Road Suite 301 Burlington, MA 01803 United States Phone: 781-305-7777 Fax: 781-202-3399 Website: http://www.flexiontherapeutics.com Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
FLXN Latest News
  • No Recent News Available for this company!
New Post